Science

OXFORD UNIVERSITY PRESS                                                                                  Dec, 10, 2014

In an editorial published online today in the International Journal of Epidemiology, experts from the Departments of Psychiatry and Epidemiology at Columbia University, New York, are calling for survivors of the Ebola epidemic to be mobilised in a bid to hasten containment of the disease.

We already know that the current Ebola outbreak is unique in its magnitude and for its dispersion in dense, mobile populations. Physicians and nurses face high mortality, and foreign aid in the form of medical supplies and staff continues to be unequal to the scope of the problem. With a case recovery rate of around 30% at the present time in West Africa, survivors already number in the thousands.

REPORTS Of RESEARCH ON TWO METHODS OF RAPID TESTING FOR EBOLA

(Two items, scroll down)

MEDICAL PRESS                                                                                     Dec. 8, 2014

Rutgers researcher David Alland, working with the California biotechnology company Cepheid, has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola.

Researchers will adapt this cartridge, now used worldwide for tuberculosis screenings, to collect and test samples from potential Ebola patients. Credit: John Emerson

Alland, a professor of medicine and associate dean for clinical research at Rutgers New Jersey Medical School and the principal investigator of the project, says health workers would be able to take the test to small villages and other remote locations where the spread of Ebola has been especially rampant and diagnose patients where they live...

by Shalini Saxena - Nov 30 2014 - http://arstechnica.com

We know what antibodies stop it in its tracks—we now know where they attach.

The latest Ebola outbreak has dwarfed any that have occurred since the discovery of the virus in 1976; previous outbreaks have had lethality rates of up to 90 percent. Yet no vaccines or therapies are currently approved for human use, which limits our ability to treat patients and contain the outbreak. Mixtures of monoclonal antibodies (see sidebar) are a potential treatment option that has been used experimentally.

ASSOCIATED PRESS                                                                                                  Nov. 18, 2014

A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa.

This Nov. 7, 2014, photo shows the inside a mobile donation unit at the Raleigh-Durham International Airport in Raleigh, N.C. The unit was headed to Africa for use in a study of blood plasma treatment for Ebola patients. (AP Photo/Trevor Jenkins) (The Associated Press)

Plasma from survivors contains antibodies, substances the immune system makes to fight the virus. Several Ebola patients have received survivor plasma and recovered, but doctors say there is no way to know whether it really helps without a study like the one they are about to start within a month.